Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21359253 | 1.00 | HTR2C (0.61) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL30952463 | 1.00 | HTR2C (0.61) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL14704897 | 0.89 | HTR2C (0.49) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL3777526 | 0.86 | HTR2C (0.55) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL4699360 | 0.82 | HTR2C (0.50) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL5323553 | 0.79 | HTR2C (0.57) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL4699610 | 0.79 | CYP1A2 (0.50) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL3434585 | 0.78 | HTR2C (0.61) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL4790160 | 0.78 | HTR2C (0.61) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL9530706 | 0.78 | HTR2C (0.61) | HTR2CSIGMAR1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| CN-105503869-A | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R & D IRELAND | 2016-04-20 | — | — | CN | disclosed |
| CN-103917540-B | Antibacterial piperidinyl-substituted 3, 4-dihydro-1H- [1, 8] naphthyridinones | JANSSEN R&D IRELAND (IE) | 2016-03-16 | — | — | CN | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| EP-2742047-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen R&D Ireland (IE) | 2014-06-18 | — | — | EP | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2C 2910/4885SIGMAR1 234/4885KDM4E 4854/4885 |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | NQO2, ALPI, ECI1 | HTR2C 4634/4885SIGMAR1 1357/4885KDM4E 2524/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | HTR2C 2955/4885SIGMAR1 4814/4885KDM4E 1568/4885 |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885SIGMAR1 243/4885KDM4E 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.